AI Article Synopsis
- Post-transplant lymphoproliferative disorder (PTLD) is a severe complication that can occur after hematopoietic stem cell transplantation, with primary CNS involvement being particularly rare.
- A case is presented of a patient who developed Epstein-Barr virus-related primary CNS-PTLD after transplantation and was treated with rituximab and reduced immunosuppression.
- The article also reviews existing literature and discusses various treatment options for managing primary CNS-PTLD in similar patient populations.
Article Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Extra nodal involvement is common in PTLD, but isolated involvement of the central nervous system (CNS) is extremely rare. Given the rarity of primary CNS-PTLD there is no consensus on optimal treatment. We report a patient who developed Epstein-Barr virus related primary CNS-PTLD following allogeneic HSCT who was treated with the monoclonal anti-CD20 antibody rituximab and reduction of immunosuppression. In addition, we review the literature and discuss treatment options for patients with primary CNS-PTLD following allogeneic HSCT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11060-011-0739-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review.
Diagn Pathol
September 2024
Department of Hematology, Qilu Hospital of Shandong University, 107 West Wenhua Road, Jinan, Shandong, 250012, China.
Article Synopsis
- Post-transplant lymphoproliferative disorders (PTLD) are serious complications following organ transplants, particularly difficult to diagnose in the central nervous system (CNS) and associated with high mortality rates.
- The case study focuses on a patient with EBV-related CNS-PTLD and evaluates treatment effectiveness through a systematic review of 431 similar cases.
- Findings show that rituximab combined with EBV-specific therapies has a high response rate, suggesting it could be a promising treatment option for managing PTLD after transplants.
Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry.
Transplant Direct
June 2024
Worldwide Health Economic and Outcomes Research, Bristol Myers Squibb, Princeton, NJ.
Background: Belatacept, a selective T-cell costimulation blocker, was associated with improved survival and renal function but also with a risk of posttransplant lymphoproliferative disorder (PTLD) in adult kidney transplant recipients in phase 3 trials. This registry examined long-term safety in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients treated with belatacept.
Methods: This US-based, prospective, voluntary, multicenter registry (Evaluating Nulojix Long-Term Safety in Transplant [ENLiST]) included adult EBV-seropositive kidney-only transplant recipients treated de novo (within 14 d of transplantation) with belatacept.
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Ann Hematol
August 2021
Department of Haematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Gröpelinger Heerstr. 406-408, 28239, Bremen, Germany.
Post-transplant lymphoproliferative disorders (PTLD) exclusively affecting the central nervous system-primary CNS-PTLD (pCNS-PTLD)-are rare. There is no standard therapy, and previous case series have included heterogeneous treatment approaches. We performed a retrospective, multi-centre analysis of 14 patients with pCNS-PTLD after solid organ transplantation (SOT) treated in the prospective German PTLD registry with reduction of immunosuppression (RI), whole-brain radiotherapy (WBRT), and concurrent systemic rituximab between 2001 and 2018.
View Article and Find Full Text PDFPrimary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients.
Br J Haematol
June 2021
Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
Primary central nervous system (CNS) post-transplant lymphoproliferative disorder (PTLD) in childhood is rare. Twenty-five patients were retrieved from nine European Intergroup for Childhood Non-Hodgkin's Lymphoma and/or international Berlin-Frankfurt-Münster Study Group members. Types of allografts included kidney (n = 11), liver (n = 4), heart (n = 5), bowel (n = 1) and haematopoietic stem cells (n = 4).
View Article and Find Full Text PDFToxoplasmic Encephalitis Followed by Primary EBV-Associated Post-Transplant Lymphoproliferative Disorder of the Central Nervous System in a Patient Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Report.
Transplant Proc
November 2020
Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Article Synopsis
- Toxoplasmic encephalitis (TE) and post-transplant lymphoproliferative disorder of the central nervous system (CNS-PTLD) are serious complications that can occur after an allogeneic stem cell transplant and require prompt diagnosis and treatment to avoid fatal outcomes.* -
- A 51-year-old man with a history of myelodysplastic syndrome developed TE, confirmed by positive PCR for Toxoplasma gondii in cerebrospinal fluid, and initially improved with anti-Toxoplasma therapy.* -
- Later, he experienced new neurological symptoms leading to a brain biopsy, which diagnosed him with CNS-PTLD (not TE), and he successfully underwent treatment involving reduced immunosuppression
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!